Search tips
Search criteria 


Logo of oncotargetLink to Publisher's site
Oncotarget. 2016 December 6; 7(49): 80336–80349.
Published online 2016 September 13. doi:  10.18632/oncotarget.12015
PMCID: PMC5340253

SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status


The observation that cellular transformation depends on breaching a crucial KRAS activity threshold, along with the finding that only a small percentage of cellsharboring KRAS mutations are transformed, support the idea that additional, not fully uncovered, regulatory mechanisms may contribute to KRAS activation. Here we report that KrasG12D mice lacking Sirt2 show an aggressive tumorigenic phenotype as compared to KrasG12D mice. This phenotype includes increased proliferation, KRAS acetylation, and activation of RAS downstream signaling markers. Mechanistically, KRAS K147 is identified as a novel SIRT2-specific deacetylation target by mass spectrometry, whereas its acetylation status directly regulates KRAS activity, ultimately exerting an impact on cellular behavior as revealed by cell proliferation, colony formation, and tumor growth. Given the significance of KRAS activity as a driver in tumorigenesis, identification of K147 acetylation as a novel post-translational modification directed by SIRT2 in vivo may provide a better understanding of the mechanistic link regarding the crosstalk between non-genetic and genetic factors in KRAS driven tumors.

Keywords: KRAS, SIRT2, acetylation, lung cancer, pancreas transformation


Sirtuin genes are the human and murine homologs of the S. cerevisiae Sir2 gene that have been shown to regulate both replicative and overall lifespan [1]. While the precise role of sirtuins in mammalian lifespan regulation is yet to be fully defined, it was recently demonstrated that male transgenic mice overexpressing SIRT6 live longer than their wild-type littermates [2]. Despite the observed discrepancies and the scarcity of detailed mechanisms regarding the role of sirtuins in longevity, it is well established that they do appear to direct critical acetylome signaling networks responding to caloric restriction (CR) [3], and following stress, several mice lacking one of the sirtuin genes develop illnesses that mimic those observed in humans that are strongly connected to increasing age [4]. Consistent with this, mice lacking Sirt2 [5] develop multiple epithelial malignancies, including pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LACA). Based on these findings, it has been suggested that sirtuins are energy/nutrient stress sensor proteins that alter the activity of downstream signaling networks and targets via post-translational modifications (PTMs) involving lysine deacetylation in response to specific types of cellular stress.

It is well established that KRAS mutations are observed in 95% of patients with PDAC [6, 7] and roughly 30% of LACA cases [7]. However, similar to most human malignancies, it is also clear that additional aberrant genetic and/or biochemical events are ultimately required for carcinogenesis. Interestingly, healthy people have cells expressing oncogenic KRAS in different organs, including the pancreas, colon, and lungs, at rates far exceeding the rates of cancer development [8, 9]. In addition, whereas the number of cells that ultimately are transformed is only a small fraction of those expressing mutant Kras (mtKras) in mouse models [10], there is emerging evidence suggesting that KRAS activity is increased in cells derived from mtKras-driven PDAC as compared to non-transformed pancreas expressing mtKras [11]. Therefore, identification of mechanisms which may contribute to breaching a crucial enzymatic KRAS activity threshold to initiate carcinogenesis, even in the presence of activating KRAS mutations, may fill the critical gap in knowledge related to KRAS-driven tumorigenesis.

Based on our previous finding that Sirt2 -/- mice develop spontaneous tumors, and a recent study showing that KRAS is acetylated in cancer cells [12], we aimed to determine the role of SIRT2 in KRAS-induced tumorigenesis in vivo. Here we report that Sirt2-/--KrasG12D mice show enhanced pancreas transformation as well as lung tumorigenesis as compared to KrasG12D mice. These phenotypes are associated with increased proliferation and KRAS acetylation as well as downstream RAS-activated signaling markers, suggesting carcinogenesis is more aggressive when Sirt2 is deleted. These results can be explained by the finding that the acetylation status of K147 directed by SIRT2 regulates KRAS's GTP-bound “active state,” as shown by using mutants that mimic either acetylation (K147Q) or deacetylation (K147R). The effect of K147 acetylation on KRAS activity impacts both the transformative and oncogenic properties of KRAS. These results, together with the fact that K147 acetylation can be detected in tissues in vivo, highlight the role of this reversible PTM in regulating KRAS activity, and, more importantly, identify for the first time K147 acetylation as an oncogenic modification directed by SIRT2.


Deletion of Sirt2 induces KRAS-mediated pancreas transformation

To determine the role of SIRT2 in KRAS-induced pancreas transformation, the pancreatic epithelium-specific KrasG12D mice, which were generated using the well-established LSL-KrasG12D knock-in mouse model [13] and the Ptf1Cre driver line [14] to direct recombination in pancreas, were crossed with Sirt2-/- mice [5] to generate Sirt2+/+;LSL-KrasG12D;Ptf1Cre and Sirt2-/-;LSL-KrasG12D;Ptf1Cre mice (referred to here as KrasG12D-Ptf1 and Sirt2-/--KrasG12D-Ptf1 mice, respectively). At 4 months of age, the Sirt2-/--KrasG12D-Ptf1 mice exhibited a complete loss of normal glandular architecture, with no discernible normal tissue (Figure (Figure1A1A right, see absence of normal tissue (n)). This abnormal architecture was accompanied by severe fibrosis (Figure S1A, right panel) as observed by trichrome staining, especially around areas with detectable pancreatic lesions. Histopathologic analyses revealed that all mice developed pancreatic intraepithelial neoplasia (PanIN) of different grades (Figure (Figure1B).1B). However, Sirt2-/--KrasG12D-Ptf1 mice showed an increase in induction and PanIN progression compared to KrasG12D-Ptf1 mice as revealed by the amount and grade of these lesions both at 4 and 6 months of age (Figure (Figure1C).1C). This is consistent with a tumor suppressor role of SIRT2 in the pancreas, which is also in line with lower SIRT2 mRNA levels detected in pancreatic adenocarcinoma compared to normal tissue (Figure S1B).

Figure 1
Mice lacking Sirt2 and expressing mtKras exhibit enhanced development of PanIN and progression to PDAC

To explore whether the Kras-induced pancreas transformation found in Sirt2-/- mice is due to a cell autonomous mechanism, we generated Sirt2 conditional knockout (Sirt2fl/fl) mice (Figure S1C-E) that were crossed with the LSL-KrasG12D;Ptf1Cre mouse model to study the effect of pancreatic epithelium-specific Sirt2 deletion in the KrasG12D knock-in mouse model. Histopathologic analyses showed similar patterns of induction and PanIN progression in both the Sirt2fl/fl-KrasG12D-Ptf1 and Sirt2-/--KrasG12D-Ptf1 mice (Figure 1D, 1E), suggesting that SIRT2 acts autonomously in pancreatic cells. Of note, some Sirt2-/--KrasG12D-Ptf1 mice (two out of ten) developed areas of PDAC at 8 months of age (Figure (Figure1F),1F), an acceleration of the timeframe of PDAC development in KrasG12D-Ptf1 mice (≥1 year). In addition, these mice contained areas of tumor cells that appeared disorganized and were surrounded by dense fibrosis, as evidenced by a robust desmoplastic response (Figure (Figure1F1F).

Oncogenic KRAS activates a plethora of signaling pathways, including the canonical Raf/MEK/ERK pathway. Lesions from both KrasG12D-Ptf1 and Sirt2-/- -KrasG12D-Ptf1 mice that were confirmed to be of pancreatic origin after positive staining with CK19, were also stained for phosphorylated ERK (pERK) as an indirect marker of KRAS activity in these mice (Figure (Figure1G).1G). Sirt2-/--KrasG12D-Ptf1 pancreas showed higher pERK levels compared to KrasG12D-Ptf1 mice, indicating that deletion of Sirt2 is associated with increased downstream KRAS signaling. Finally, proliferation analysis using BrdU labeling showed active proliferation in Sirt2-/--KrasG12D-Ptf1 pancreas as compared to KrasG12D-Ptf1 pancreas (Figure 1G, 1H). All these data together further indicate that loss of Sirt2 induces KRAS-mediated pancreas transformation.

Deletion of Sirt2 increases KRAS-induced lung adenocarcinoma

To determine the role of SIRT2 in KRAS-dependent lung adenocarcinoma, the well-established LSL-KrasG12D knock-in mouse model was crossed with Sirt2-/- mice to generate Sirt2+/+;LSL-KrasG12D and Sirt2-/-;LSL-KrasG12D mice (referred to here as KrasG12D and Sirt2-/--KrasG12D mice, respectively) followed by intranasal administration of adenoviral Cre (adenoCRE) to induce mtKras expression in the lungs [15]. Examination of the lungs in a cohort of untreated Sirt2-/--KrasG12D mice as well as KrasG12D and Sirt2-/--KrasG12D mice 4 months after exposure to adenoCRE revealed that Sirt2-null mice had a significantly greater number of tumor lesions in the lungs (Figure 2A, 2B), as well as larger tumor area (Figure (Figure2C),2C), than KrasG12D mice.

Figure 2
Loss of Sirt2 enhances KRASG12D-induced lung adenocarcinoma and KRAS acetylation is associated with increased activity in vivo

Histopathologic examination of lungs at an earlier time point after adenoCRE administration showed similar results. In particular, 2 months after adenoCRE administration, the Sirt2-/--KrasG12D mice lungs exhibited increased numbers of tumor cell nests per 10x field (Figure S1F) and increased tumor size (Figure S1G). Histopathological analyses showed that Sirt2-/--KrasG12D mice clearly developed lung tumors (Figure S1H, two right panels), as compared to mostly scattered areas of atypical adenomatous hyperplasia (AAH) developed in the KrasG12D mice (Figure S1H, two left panels). The tumors were adenocarcinomas, as determined by thyroid transcription factor-1 staining (data not shown). Furthermore, Sirt2-/--KrasG12D serial lung sections showed nests of tumor cells exhibiting increased in vivo pERK (Figure S1I, middle panels) and Ki-67 staining (Figure S1I, right panels), implying increased KRAS activity and tumorigenicity in the lungs when Sirt2 is deleted. Collectively, these results suggest that Sirt2 deletion enhances the progression of oncogenic KRAS-induced lung adenocarcinomas.

Increased acetylation of KRAS due to Sirt2 loss is associated with increased KRAS activity

To start unraveling the mechanistic details regarding either the direct or indirect effect of SIRT2 on KRAS, we checked whether there is a direct interaction between the two proteins. Of note, we detected interaction of the two proteins in both pancreas and lung (Figure (Figure2D)2D) tissues found to exhibit enhanced KRAS-mediated transformation and/or tumorigenicity when Sirt2 was lost, as presented earlier. The presence of both proteins in the same complex was further confirmed in reciprocal co-immunoprecipitation experiments after overexpressing both KRAS and SIRT2 in 293T cells (data not shown), as well as after checking endogenous proteins in Sirt2+/+ primary MEFs (Figure S2A). Furthermore, KRAS was detected to specifically interact with SIRT2 but not other members of the sirtuin family (Figure S2B, C) arguing for a direct regulatory function of SIRT2 on KRAS. More importantly, tissues depleted of Sirt2 exhibited a significant increase in KRAS acetylated levels which was further associated with increased KRAS activity (Figure 2E-2G). In particular, GTP-bound “active” KRAS, detected through a specific protein interaction with the Raf1 Ras-binding domain (Raf1-RBD), was enriched in the Sirt2-/- tissues. Under the same experimental conditions, enhanced KRAS activity was associated with increased pERK levels (Figure 2E-2G), further establishing the positive effect of KRAS acetylation on its activity in vivo. Taken together, these results favor the scenario of KRAS being a SIRT2 deacetylation target in vivo. The generality of the regulatory role of SIRT2 in KRAS signaling was also confirmed in Sirt2-/- MEFs (Figure S2D). In addition, in HCT116 cells, which express a wild-type and a mutant Kras allele, infection with lenti-shSIRT2 increased both KRAS activity, as evidenced by increased pERK levels (Figure S2E), and colony formation, as revealed by enhanced growth in soft agar (Figure S2F, G).

To establish KRAS as a legitimate SIRT2 deacetylation target, a series of cell culture experiments were performed. To assess whether SIRT2 deacetylates KRAS, 293T cells were co-transfected either with HA-KRAS or HA-KRASG12V, with wild-type Flag-SIRT2, as well as with p300/CBP based on our results showing that these two are the main histone acetyl transferases (HATs) to acetylate KRAS (Figure S2H). Following immunoprecipitation with an anti-acetyl-lysine (Ac-K) antibody, both wild-type and KRASG12V were deacetylated by SIRT2 (Figure S2I, lane 3 vs lane 2 and lane 6 vs lane 5, respectively). Increased KRAS activity upon treatment with both nicotinamide, an inhibitor of all members of the sirtuin family, and AGK2, a specific SIRT2 inhibitor (Figure S2J), highlights the unique role of SIRT2 among other sirtuins as a regulator of KRAS activity. Finally, KRAS activity was decreased in co-transfection experiments using wild-type SIRT2 (SIRT2wt), but not a SIRT2 deacetylation null mutant gene (SIRT2dn) (Figure S2K), suggesting that SIRT2 regulates KRAS activity through its deacetylation activity. Interestingly, the same effect on KRASG12V activity was observed (data not shown), implying that both wild-type and mutant KRAS can be regulated through SIRT2-mediated deacetylation. Together these results demonstrate that KRAS contains a reversible acetyl-lysine and aberrant regulation of KRAS when SIRT2 is lost may result in induced KRAS activity.

Acetylation status of K147 directs KRAS activity and transformative properties

To identify specific SIRT2 target lysines, lysates from 293T cells expressing either Flag-KRASG12V alone (sample 1) or Flag-KRASG12V and SIRT2 (sample 2) were run on a gel and bands corresponding to the molecular weight of Flag-KRAS were excised and analyzed by mass spectrometry (Figure S3A-C). In the absence of SIRT2 (Figure S3A, sample 1), acetylated lysines 104 and 147 (K104, K147 in red circles) were detected with the peptides identified under this condition (highlighted in yellow). When SIRT2 was overexpressed (Figure S3A, sample 2), K147 acetylation was undetectable in contrast to K104 acetylation, implying that K147 is a SIRT2-specific reversibly acetylated lysine target.

It has been previously shown that substitution of a lysine with a glutamine mimics the acetylated state, while substitution with an arginine mimics deacetylation [16]. For this, we generated K147Q and K147R KRAS mutants to determine the effect of K147 acetylation on KRAS activity. The KRAS mutants were expressed in Kraslox MEFs (Hras-/-;Nras-/-;Kraslox/lox;RERTnert/ert) where the conditional Kraslox alleles are fully excised upon expression of the Cre recombinase, inducible in the presence of 4-hydroxytamoxifen (4HT), resulting in Rasless MEFs [17]. In particular, Kraslox MEFs were infected with lenti-KRAS, lenti-KRASK147R, lenti-KRASK147Q, lenti-KRASG12V, lenti-KRASG12V-K147R and lenti-KRASG12V-K147Q and subsequently treated with 4HT, resulting in cells expressing only the lentiviral constructs of KRAS and KRASG12V. Cell proliferation rate was significantly higher in MEFs expressing KRAS after knocking down Sirt2 consistent with increased KRAS activity detected in these cells, whereas decreased Sirt2 expression didn't affect proliferation in MEFs expressing either KRASK147R or KRASK147Q (Figure 3A-3D). Next we examined the impact of K147 acetylation status in both wild-type KRAS and mutant KRASG12V. MEFs expressing KRASK147Q exhibited increased amounts of “active” GTP bound KRAS, as measured by the Ras pulldown assay, compared to the KRAS and KRASK147R infected cells (Figure (Figure3E,3E, left), suggesting that acetylation enhances wild-type KRAS activity. In cells expressing KRASG12V, expression of KRASG12V-K147Q produced an increase in the amount of active protein compared to KRASG12V, whereas less active protein was observed with expression of KRASG12V-K147R. (Figure (Figure3E,3E, right). The effect of K147 acetylation status on KRAS activity was confirmed in 293T cells after transient overexpression of the KRAS and KRASG12V acetylation mutants (data not shown). MEFs expressing KRASK147Q exhibited increased proliferation as determined by measuring the number of cells and colonies (Figure 3F-3H), compared to cells expressing either KRAS or KRASK147R. In KRASG12V expressing MEFs, KRASG12V-K147Q increased the proliferation rate, whereas KRASG12V-K147R exerted the opposite effect (Figure 3F-3H).

Figure 3
K147 acetylation status directed by SIRT2 regulates KRAS dependent proliferation

To determine the impact of K147 acetylation status on KRAS transformative properties, NIH3T3 cells expressing KRASG12V acetylation mutants after knocking down endogenous Kras were constructed. Of note, NIH3T3 cells expressing KRASG12V-K147Q exhibited increased proliferation (Figure S4A-C), consistent with previous results in MEFs, excluding the possibility that the observed differences in proliferation could be attributed either to the different integration sites after viral infection or to a cell type-specific phenomenon. More importantly, these cells formed more colonies when grown both under confluence and in soft agar (Figure 4A-4C), indicating enhanced transforming activity of KRAS upon K147 acetylation. To further establish that K147 acetylation is an oncogenic PTM, both NIH3T3 cells and Rasless MEFs expressing the different KRASG12V acetylation mutants were used for subcutaneous injections into nude mice, and tumor growth was monitored. In accordance with the cell culture results, KRASG12V-K147Q-expressing cells exhibited a significant increase in tumor growth rate relative to cells expressing KRASG12V, as evidenced by the increased volume of tumors developed in these mice (Figure 4D-4H and Figure S4D, E).

Figure 4
K147 acetylation status regulates KRAS transformative properties

K147 acetylation alters the nucleotide exchange kinetics of KRAS

K147 is located within the functionally important G5 box, a critical peptide sequence for the formation of the nucleotide binding site in RAS proteins [18]. Mutation of the adjacent A146 has been shown to activate the transforming potential of KRAS by significantly increasing the nucleotide exchange rate [19]. To shed light on the biochemistry related to the enhanced KRAS activity detected when K147 is mutated to glutamine (resembling the acetylated status), we employed a method using fluorescently labeled GDP and GTP analogues to measure the nucleotide exchange kinetics of KRAS mutants (Figure (Figure5A).5A). The increase in fluorescence intensity when N-methylanthraniloyl (mant)-labeled GDP and GTP bind to purified KRAS, KRASK147Q, KRASG12V and KRASG12V/K147Q allows monitoring of nucleotide exchange in real time. Both KRASK147Q and KRASG12V/K147Q exhibited an increased rate of nucleotide exchange compared to KRAS and KRASG12V, respectively (Figure 5B, 5C). Given the higher intracellular concentration of GTP compared to GDP, this may explain the increased GTP-bound “active” KRAS detected when K147 is acetylated.

Figure 5
The effect of K147 acetylation on the nucleotide exchange rate along with its detection in vivo support the physiological significance of this post-translational modification

These results were confirmed when a similar approach was followed using extracts from cells expressing Flag-tagged KRAS or KRASK147Q. In this case, extracts were treated with 2 μM GDP, resulting in loading of both KRAS and KRASK147Q with GDP, and exchange reactions in the presence of EDTA - catalyzed off- were carried out after adding increasing amounts of GTP. GTP-bound KRAS and KRASK147Q were then assessed by immunoprecipitation using Raf1-RBD agarose beads (Figure (Figure5D).5D). In accordance with our previous results, KRASK147Q showed enhanced GDP exchange for GTP compared to KRAS (Figure (Figure5E),5E), suggesting that K147 acetylation may alter the nucleotide exchange kinetics favoring the active KRAS state.

K147 acetylation is a PTM that can be detected in tissues

We previously observed increased KRAS acetylation levels in tissues when Sirt2 is lost (Figure 2E-2G). However, acetylation was detected in those experiments using a general pan Ac-K antibody. We now tested whether K147 is specifically acetylated in Sirt2-/- tissues using a custom-made polyclonal antibody against acetylated K147 (Ac-K147) of KRAS. The specificity of the antibody against KRAS Ac-K147 was checked in vitro via dot blot (Figure S5A) as well in cell culture experiments (Figure S5B-E) where K147 acetylation was detected both after overexpressing KRAS and after checking endogenous KRAS. Therefore, after completing the validation process, immunoprecipitation experiments using the anti Ac-K147 antibody in pancreas from both KrasG12D-Ptf1 and Sirt2-/--KrasG12D-Ptf1 mice revealed that K147 acetylation is a PTM that can be detected in vivo (Figure (Figure5F),5F), highlighting the physiological significance of this modification. Then, after checking whether this newly developed antibody is suitable for immunohistochemistry (Figure S5F), pancreas from mice with the genotypes described above were stained. Consistently, we detected increased K147 acetylation in pancreas where Sirt2 is lost (Figure (Figure5G).5G). Interestingly, besides pancreatic lesions that were stained positively for K147 acetylation, the majority of normal acinar cells in the Sirt2-/—KRASG12D-Ptf1 mice that were not yet transformed were stained strongly with the anti Ac-K147 antibody, and this was further associated with phosphorylation of ERK (Figure S5G), suggesting that K147 acetylation may be an early event in KRAS-induced tumorigenesis in the context of Sirt2 deletion. Under these conditions, enhanced downstream KRAS signaling could contribute to enhanced induction of acinar to ductal metaplasia (ADM), as a result of the direct effect of K147 acetylation on KRAS activity.


Based on the well-established observation that increasing age is the most significant risk factor for tumor development, intense research efforts have focused on the role played by sirtuins as the mechanistic link between aging and tumorigenesis. Regarding SIRT2, we have previously shown that Sirt2-deficient mice develop tumors in several tissues, providing the first strong genetic evidence that SIRT2 may function as a tumor suppressor through its role in regulating the anaphase-promoting complex/cyclosome (APC/C) [5]. Although additional studies further support the tumor-suppressive role of SIRT2 [20], it is worth mentioning that SIRT2 has been shown to exert dual functions where it seems to have oncogenic properties as well [21, 22]. This highlights the complexity of sirtuin biology implying that additional aberrant genetic and/or biochemical events are required for and need to be identified to untangle the role of SIRT2 in tumorigenesis, especially within a tissue-specific and genetic context.

Here, we demonstrate that SIRT2 functions as a tumor suppressor in the context of KRAS-dependent tumorigenesis. Mechanistically, we propose that K147 acetylation may increase KRAS activity and exerts a significant impact on cellular behavior as evidenced by increased proliferation, colony formation ability, anchorage independent growth and, finally, tumor growth rate in cells expressing a K147Q KRAS mutant resembling the acetylated state. These results, together with the confirmed detection of K147 acetylation in tissues using our anti-Ac-K147 KRAS antibody, reveal for the first time the role of K147 acetylation in vivo as a novel KRAS PTM directed by SIRT2. Sirtuins are deacetylation enzymes and as such they have been found to regulate a plethora of substrates with SIRT2 not being an exemption. Thus, it is expected that additional pathways may contribute either synergistically or independently to KRAS-induced tumorigenesis. In this study we provide evidence to further establish the tumor-permissive phenotype observed in mice lacking Sirt2, and we show that K147 KRAS acetylation upon Sirt2 loss plays a significant role in driving cellular transformation and aberrant growth, at least, in tissues where increased Ras activity has been proven to be a driver for tumorigenesis.

KRAS is the most frequently mutated oncogene in human cancer [23], which justifies the intensive efforts made to elucidate regulatory mechanisms, signaling transduction, feedback loops, isoform differences, and heterogeneity regarding the mutational landscape, as well as to exploit vulnerabilities in RAS-related tumors [24]. Here we show that K147 acetylation is a PTM directly affecting KRAS activity rather than protein localization, as commonly happens with other PTMs such as farnesylation [25]. This finding, together with recently published studies showing that both K104 acetylation [12] and K147 mono-ubiquitination [26] regulate KRAS activity, even though it is still unknown whether these PTMs play any role in KRAS tumors in vivo, indicates that we are just starting to understand and evaluate the contribution of PTMs to fine-tuning KRAS activity. In this regard, the well-known tumor suppressor p53 showcases how complex this regulatory network of PTMs might be [27]. With regard to KRAS, K147Q, which resembles K147 acetylation, increases the SOS-independent nucleotide exchange rate, whereas K147 mono-ubiquitination doesn't affect intrinsic nucleotide dissociation. Instead it impedes GAP-mediated GTP hydrolysis, resulting in Ras activation [28]. The difference in the biochemistry implies that acetylation and mono-ubiquitination exert their impact on KRAS through different mechanisms. Moreover, if the effect of acetylation was through regulating ubiquitination, it would be expected that K147 acetylation (or K147 mutation) would prevent mono-ubiquitination, resulting in decreased KRAS activity. However this is not supported by our experimental results, which further establishes the independent function of these PTMs. Regarding K104 acetylation, biochemical characterization revealed that K104 acetylation renders KRAS more resistant to SOS-dependent nucleotide exchange [12, 29], even though the effect on KRAS activity hasn't been tested directly. Consistent with previous reports, we could detect K104 acetylation in cells overexpressing KRASG12V. However, our mass spectrometry analysis revealed K147 acetylation as a reversible lysine acetylation which is specifically deacetylated by SIRT2. Based on our biochemical, cell behavior and, most importantly, in vivo analyses, we show that K147 acetylation may exert a positive effect on KRAS activity (in contrast to the decreased KRAS activity proposed upon K104 acetylation), which results in enhanced KRAS-induced tumorigenesis in mouse models. The opposing effect of the acetylation of these two sites, at least at the biochemical level, indicates the distinct nature of the PTMs, which might be reflected at the molecular and cellular levels with respect to enzymes involved in acetylation/deacetylation as well as physiological conditions under which these PTMs regulate KRAS activity.

Consistent with previous studies showing that K147 is within a conserved sequence critical for the formation of the nucleotide binding site [18], we found a significant increase in the nucleotide exchange rate when K147 was mutated to glutamine, which resembles acetylated K147. Given the higher intracellular concentration of GTP, it can be suggested that acetylation of wild-type KRAS may result in a more frequent auto-activation by spontaneously exchanging GDP for GTP, leading to increased aberrant RAS signaling. This could increase mutant KRAS activity as well, based on the observation that most KRAS mutants retain some intrinsic GTPase activity, despite their insensitivity to GAP-mediated GTP hydrolysis, implying that increased nucleotide exchange could positively regulate KRAS activity. The idea that an increase in nucleotide exchange can act synergistically with decreased GTPase activity is supported by data showing that strongly activating mutations in terms of transforming potential represent a combined effect of reduced GTPase activity and increased exchange [19]. Taking this into account and in the context of a recently proposed classification of different KRAS mutations based on biochemical characterization [30], we could predict that some KRAS mutations, such as G12C, G12D, and G12V, would be affected more by K147 acetylation, based on the undetectable effect on nucleotide exchange and the modest effect on GTP hydrolysis compared to other mutations. Moreover, the finding that KRAS K147 seems to be a specific deacetylation target of SIRT2 raises some novel, yet undiscovered, possibilities regarding the crosstalk between non-genetic and genetic factors in KRAS-induced tumors. Taking into consideration that sirtuins respond to both environmental stress and nutrient availability, whereas their activity is altered with aging, it would be trivial to determine in the future whether the SIRT2-directed acetylation status of K147 can, at least in some part, mediate the effects of non-genetic factors known to affect KRAS-induced tumorigenesis [31], [32], [33] providing an additional layer of regulation.

Taking into account the regulatory role of SIRT2, we present here evidence to further establish the tumor suppressor role of SIRT2 in a KRAS-specific context by proposing that the acetylation status of K147 may direct activity and transformative properties. Both in vitro assays and in vivo mouse models, as well as data showing that K147 acetylation can be detected in vivo, underscores the significance of unraveling the molecular and cellular events related to PTMs which may directly fine-tune KRAS activity. Given the so far unsuccessful attempts to therapeutically target KRAS, stemming from the difficulty of predicting which of the many downstream effector pathways is engaged under specific conditions, the deeper understanding of mechanisms regulating RAS activity itself could fill critical knowledge gaps in the RAS biology field. Furthermore, identification of K147 acetylation as a novel post-translational modification directed by SIRT2 may provide a better understanding of the mechanistic link regarding the crosstalk between non-genetic and genetic factors in KRAS driven tumors. Thus it is reasonable to suggest that conditions known to affect sirtuin activity may further regulate KRAS activity and signal output through K147 acetylation even in the presence of mutant KRAS. In this regard and towards possible therapeutic implications, our in vivo experimental results suggest that decreasing KRAS acetylation through increased SIRT2 activity could be an approach to limiting tumorigenic potential of KRAS-driven tumors.



A description of all mice used in this study, as well as details regarding the generation of the Sirt2fl/fl mice, can be found in the Supplementary Materials and Methods section. Mice were housed, fed and treated in accordance with the guidelines approved by the Northwestern University IACUC.


Lung and pancreas tissues were harvested and fixed with 10% formalin. Tissues were paraffin embedded, and 4 μm sections were cut and stained with hematoxylin and eosin (H&E) in the Mouse Histology & Phenotyping Laboratory (MHPL) at Northwestern University. Details regarding the protocol for immuhostochemistry can be found in the Supplementary Materials and Methods.

Cell culture

NIH/3T3 (ATCC® CRL­1658™), 293T (ATCC® CRL-3216) and HCT116 (ATCC® CCL-247) cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS) with antibiotics at 37°C in a humidified atmosphere containing 5% CO2 and 95% O2. Cell lines were authenticated using CellCheck by IDEXX Bioresearch, and tested for mycoplasma using PlasmoTest™ - Mycoplasma Detection Kit (InvivoGen, Inc). Hras-/-;Nras-/-;Kraslox/lox;RERTert/ert MEFs were kindly provided by Mariano Barbacid (Spanish National Cancer Research Centre) and were maintained as described previously [17]. Immortalized Sirt2+/+ and Sirt2-/- MEFs were made as described previously [5]. Cell lines were cultured for less than 20 passages and frozen down from the first 3 passages for further experiments.

In vivo BrdU incorporation

For in vivo BrdU labeling, mice were injected intraperitoneally with 50 mg/kg of BrdU in PBS, pH 7.6, and were sacrificed 1.5 h later. Pancreata were isolated and fixed in 10% formalin, embedded in paraffin, and processed by routine procedures. BrdU incorporation was detected by immunohistochemistry using BrdU antibody (Sigma) according to the manufacturer's instructions.

RAS activity

GTP-bound “active” KRAS was determined by using the Thermo Scientific Active Ras Pull-Down and Detection Kit (Thermo Scientific) according to the manufacturer's instructions. A GST-fusion protein of the RAS-binding domain (RBD) of Raf1 along with glutathione agarose resin is used to specifically pull down active RAS.

Intranasal infection

After anesthetization of KrasG12D and Sirt2-/-;KrasG12D mice using isofluorane, replication-deficient adenovirus expressing Cre recombinase (adenoCRE; Gene Transfer Vector Core, University of Iowa) was administered intranasally. A detailed description of the protocol can be found in the Supplementary materials and methods


Cells or tissue samples were lysed using immunoprecipitation (IP) buffer (25mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, and 5% glycerol). After protein quantification using the Bradford assay, cell extracts (500 μg - 1 mg total protein) were incubated overnight with appropriate antibodies followed by incubation with protein A or G agarose beads for 4 h at 4 °C. After washing five times with IP buffer, immunocomplexes were resolved using SDS-PAGE and analyzed by western blotting. For immunoprecipitation the antibodies mentioned below were used: Ras (Thermo Scientific), KRAS (Proteintech), Ac-K (Immunechem), HA (Sigma), and Ac-KRAS-K147 (Eurogentec).

Cell proliferation

For measuring cell proliferation, the MTT- [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] proliferation assay, cell number counting and colony formation ability were determined using the assays described in Supplementary Materials and Methods.

Cellular transformation

Transformation ability of NIH3T3 cells was assessed by checking colonies formed by confluent cells as well as by observing anchorage-independent growth in soft agar. A detailed description of the assays used can be found in the Supplementary Materials and Methods.

Tumor growth analysis

NIH3T3 cells (1 × 106) or MEFs (2 × 106) were subcutaneously injected in each flank of 4-6 week-old male nude athymic mice (nu/nu) (Jackson Laboratory) in 200 μL PBS. Tumor sizes were determined every 1-2 days (NIH3T3) or 3-4 days (MEFs) by measuring the length (l) and the width (w) of each tumor with an electronic caliper. Tumor volume (V) was calculated using the formula V = lw2/2. Mice were housed, fed, and treated in accordance with the guidelines approved by the Northwestern University IACUC.

Nucleotide exchange assay

Each purified KRAS protein was exchanged in 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM b-mercaptoethanol using PD10 desalting columns (GE Healtcare). Protein samples were, next, incubated with 5 mM GDP (50-fold molar excess) in the presence of 20 mM EDTA. For the nucleotide exchange assay, 2 μM GDP-loaded KRAS and 4 μM mant-GTP or mant-GDP were mixed in the assay buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM β-mercaptoethanol, 10 mM MgCl2, 20 mM EDTA) and dispensed into a 384-well plate. Fluorescence was measured every 4 s for 15 min at excitation/emission set to 360 nm/440 nm in a Spectramax M3 plate reader (MolecularDevice). Data were exported and analyzed using Graphpad Prism (GraphPad Software, Inc., La Jolla, CA). All readings were performed in triplicate.

Statistical analysis

Statistical significances were determined by comparing means of different groups using unpaired t test or two-way ANOVA followed by post-tests. Graph Pad Prism 6 (Graphpad Software Inc. La Jolla, CA) was used for statistical analysis.



We would like to thank the members of the Vassilopoulos lab for critically reading the manuscript and Melissa Stauffer for editing the manuscript. We thank Harold L. Moses (Vanderbilt University), Mark R. Phillips (New York University), Lewis C. Cantley (Weil Cornell Medical College) and Mariano Barbacid (Spanish National Cancer Research Centre) for providing mice, plasmids, and cells used in this study. Also we would like to thank Kristie Linsey Rose (MSRC Proteomics Laboratory, Vanderbilt University) for assistance with the mass spectrometry analysis as well as Paul J. Grippo (Gastroenterology and Hepatology, Department of Medicine, UIC) and members of his lab for helping us with preparation and examination of pancreas histological sections.



The authors report no conflicts of interest pertaining to this study.


D. Gius was supported by NCI-1R01CA152601-01, 1R01CA152799-01A1, 1R01CA168292-01A1 and the Hirshberg Foundation. A. Vassilopoulos was supported by R01CA182506-01A1, a Lefkofsky Family Foundation Innovation Research Award and the Lynn Sage Foundation.

Editorial note

This paper has been accepted based in part on peer-review conducted by another journal and the authors’ response and revisions as well as expedited peer-review in Oncotarget.


1. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature. 2001;410:227–30. doi: 10.1038/35065638. [PubMed] [Cross Ref]
2. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483:218–21. doi: 10.1038/nature10815. [PubMed] [Cross Ref]
3. Guarente L, Picard F. Calorie restriction--the SIR2 connection. Cell. 2005;120:473–82. doi: 10.1016/j.cell.2005.01.029. [PubMed] [Cross Ref]
4. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460:587–91. doi: 10.1038/nature08197. [PMC free article] [PubMed] [Cross Ref]
5. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20:487–99. doi: 10.1016/j.ccr.2011.09.004. [PMC free article] [PubMed] [Cross Ref]
6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6. doi: 10.1126/science.1164368. [PMC free article] [PubMed] [Cross Ref]
7. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–9. [PubMed]
8. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T, Threadgold J, Evans J, Gilmore I, Smart H, Lombard M, Neoptolemos J, Greenhalf W. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology. 2005;128:2124–30. [PubMed]
9. Yakubovskaya MS, Spiegelman V, Luo FC, Malaev S, Salnev A, Zborovskaya I, Gasparyan A, Polotsky B, Machaladze Z, Trachtenberg AC, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer. 1995;63:810–4. [PubMed]
10. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4:111–20. [PubMed]
11. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J, Bi Y, Grote T, Longnecker DS, Logsdon CD. Ras activity levels control the development of pancreatic diseases. Gastroenterology. 2009;137:1072–82. 82, e1–6. doi: 10.1053/j.gastro.2009.05.052. [PMC free article] [PubMed] [Cross Ref]
12. Yang MH, Nickerson S, Kim ET, Liot C, Laurent G, Spang R, Philips MR, Shan Y, Shaw DE, Bar-Sagi D, Haigis MC, Haigis KM. Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci U S A. 2012;109:10843–8. doi: 10.1073/pnas.1201487109. [PubMed] [Cross Ref]
13. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–50. [PubMed]
14. Magnuson MA, Osipovich AB. Pancreas-specific Cre driver lines and considerations for their prudent use. Cell Metab. 2013;18:9–20. doi: 10.1016/j.cmet.2013.06.011. [PMC free article] [PubMed] [Cross Ref]
15. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009;4:1064–72. doi: 10.1038/nprot.2009.95. [PMC free article] [PubMed] [Cross Ref]
16. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A. 2006;103:10224–9. doi: 10.1073/pnas.0603968103. [PubMed] [Cross Ref]
17. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, Barbacid M. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010;29:1091–104. doi: 10.1038/emboj.2010.7. [PubMed] [Cross Ref]
18. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE. 20042004:RE13. doi: 10.1126/stke.2502004re13. [PMC free article] [PubMed] [Cross Ref]
19. Feig LA, Cooper GM. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol. 1988;8:2472–8. [PMC free article] [PubMed]
20. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H, Oshimura M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2007;26:945–57. doi: 10.1038/sj.onc.1209857. [PubMed] [Cross Ref]
21. Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010;9:844–55. doi: 10.1158/1535-7163.MCT-09-0971. [PubMed] [Cross Ref]
22. McGlynn LM, Zino S, MacDonald AI, Curle J, Reilly JE, Mohammed ZM, McMillan DC, Mallon E, Payne AP, Edwards J, Shiels PG. SIRT2: tumour suppressor or tumour promoter in operable breast cancer? Eur J Cancer. 2014;50:290–301. doi: 10.1016/j.ejca.2013.10.005. [PubMed] [Cross Ref]
23. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13:828–51. doi: 10.1038/nrd4389. [PMC free article] [PubMed] [Cross Ref]
24. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014;25:272–81. doi: 10.1016/j.ccr.2014.02.017. [PubMed] [Cross Ref]
25. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2012;13:39–51. doi: 10.1038/nrm3255. [PMC free article] [PubMed] [Cross Ref]
26. Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, Haviv S, Asara JM, Pandolfi PP, Cantley LC. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal. 2011;4:ra13. doi: 10.1126/scisignal.2001518. [PMC free article] [PubMed] [Cross Ref]
27. Marouco D, Garabadgiu AV, Melino G, Barlev NA. Lysine-specific modifications of p53: a matter of life and death? Oncotarget. 2013;4:1556–71. doi: 10.18632/oncotarget.1436. [PMC free article] [PubMed] [Cross Ref]
28. Baker R, Lewis SM, Sasaki AT, Wilkerson EM, Locasale JW, Cantley LC, Kuhlman B, Dohlman HG, Campbell SL. Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nat Struct Mol Biol. 2013;20:46–52. doi: 10.1038/nsmb.2430. [PMC free article] [PubMed] [Cross Ref]
29. Yang MH, Laurent G, Bause AS, Spang R, German N, Haigis MC, Haigis KM. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol Cancer Res. 2013;11:1072–7. doi: 10.1158/1541-7786.MCR-13-0040-T. [PMC free article] [PubMed] [Cross Ref]
30. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015;13:1325–35. doi: 10.1158/1541-7786.MCR-15-0203. [PubMed] [Cross Ref]
31. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291–302. doi: 10.1016/j.ccr.2007.01.012. [PubMed] [Cross Ref]
32. Lanza-Jacoby S, Yan G, Radice G, LePhong C, Baliff J, Hess R. Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. Exp Biol Med (Maywood) 2013;238:787–97. doi: 10.1177/1535370213493727. [PubMed] [Cross Ref]
33. Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB, Ji B, Huang H, Wang H, Fleming JB, Logsdon CD, Cruz-Monserrate Z. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2013;145:1449–58. doi: 10.1053/j.gastro.2013.08.018. [PMC free article] [PubMed] [Cross Ref]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC